Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""DRUG therapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 61-80 z 463972
Tytuł:
Small molecule targeting of the p38/Mk2 stress signaling pathways to improve cancer treatment.
Autorzy:
Alimbetov D; Creehey Children's Cancer Research Institute, UT Health at San Antonio, San Antonio, USA. .
Umbayev B; Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Tsoy A; Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Begimbetova D; Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan.
Davis T; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
Kipling D; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
Askarova S; Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Sep 23; Vol. 23 (1), pp. 895. Date of Electronic Publication: 2023 Sep 23.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Humans ; Animals ; Mice ; Etoposide/pharmacology ; Etoposide/therapeutic use ; Drug Therapy, Combination ; MAP Kinase Signaling System ; Cell Survival
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study.
Autorzy:
Bjerum CM; Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Koudou BG; Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.; Centre Suisse de Recherche Scientifique en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Ouattara AF; Université Nangui Abrogoua, Abidjan, Côte d'Ivoire.; Centre Suisse de Recherche Scientifique en Côte d'Ivoire, Abidjan, Côte d'Ivoire.
Lew D; Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Goss CW; Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Gabo PT; Centre Hospitalier Régional d'Agboville, Agboville, Côte d'Ivoire.
King CL; Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.; Veterans Affairs Research Service, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, United States of America.
Fischer PU; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Weil GJ; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Budge PJ; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Pokaż więcej
Źródło:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2023 Sep 18; Vol. 17 (9), pp. e0011633. Date of Electronic Publication: 2023 Sep 18 (Print Publication: 2023).
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
MeSH Terms:
Elephantiasis, Filarial*/drug therapy
Filaricides*/adverse effects
Adult ; Animals ; Humans ; Ivermectin/adverse effects ; Albendazole/adverse effects ; Cote d'Ivoire ; Wuchereria bancrofti ; Drug Therapy, Combination ; Diethylcarbamazine/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of Helicobacter pylori Determined Using Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction.
Autorzy:
Na SY; Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Kim BW; Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Kim MJ; Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choe Y; Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Kim JS; Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2023 Sep 15; Vol. 17 (5), pp. 722-730. Date of Electronic Publication: 2022 Sep 28.
Typ publikacji:
Journal Article
MeSH Terms:
Helicobacter pylori*/genetics
Helicobacter Infections*/drug therapy
Humans ; Clarithromycin/pharmacology ; Clarithromycin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Bismuth/therapeutic use ; Oligonucleotides ; Multiplex Polymerase Chain Reaction/methods ; Retrospective Studies ; Drug Therapy, Combination ; Amoxicillin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori : A Real-World Evidence Study.
Autorzy:
Jung YS; Division of Gastroenterology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim S; Preventive Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim HY; Preventive Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Noh SJ; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Park JH; Division of Gastroenterology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sohn CI; Division of Gastroenterology, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea.
Park CH; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2023 Sep 15; Vol. 17 (5), pp. 711-721. Date of Electronic Publication: 2022 Dec 13.
Typ publikacji:
Journal Article
MeSH Terms:
Helicobacter Infections*/drug therapy
Helicobacter pylori*
Stomach Diseases*
Humans ; Amoxicillin ; Anti-Bacterial Agents/adverse effects ; Clarithromycin ; Drug Therapy, Combination ; Proton Pump Inhibitors ; Rabeprazole/adverse effects ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Optimizing Helicobacter pylori Treatment: An Updated Review of Empirical and Susceptibility Test-Based Treatments.
Autorzy:
Ishibashi F; Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Suzuki S; Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Nagai M; Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Mochida K; Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Morishita T; Department of Gastroenterology, International University of Health and Welfare Ichikawa Hospital, Ichikawa, Japan.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2023 Sep 15; Vol. 17 (5), pp. 684-697. Date of Electronic Publication: 2023 Feb 27.
Typ publikacji:
Meta-Analysis; Journal Article; Review
MeSH Terms:
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Humans ; Anti-Bacterial Agents ; Proton Pump Inhibitors ; Drug Therapy, Combination ; Clarithromycin ; Amoxicillin ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The Indian registry on current patient profiles & treatment trends in hypertension (RECORD): One year interim analysis.
Autorzy:
Rajadhyaksha GC; Department of Medicine, Topiwala National Medical College & B. Y. L. Nair Charitable Hospital, Mumbai, Maharashtra, India.
Reddy H; Department of Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.
Singh AK; Department of Cardiology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Oomman A; Department of Cardiology, Apollo Hospitals, Chennai, Tamil Nadu, India.
Adhyapak SM; Department of Cardiology, St. John's Medical College & Hospital, Bengaluru, Karnataka, India.
Pokaż więcej
Źródło:
The Indian journal of medical research [Indian J Med Res] 2023 Sep; Vol. 158 (3), pp. 244-255.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Antihypertensive Agents*/therapeutic use
Hypertension*/drug therapy
Hypertension*/epidemiology
Male ; Humans ; Middle Aged ; Female ; Quality of Life ; Prospective Studies ; Drug Combinations ; Blood Pressure ; Treatment Outcome ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
Autorzy:
Lamy A; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, Canada.; Department of Surgery, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Eikelboom J; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Tong W; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; CADENCE Research Group, Hamilton Health Sciences, Hamilton, Ontario, Canada.
Yuan F; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Bangdiwala SI; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Bosch J; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Connolly S; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Lonn E; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Dagenais GR; Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Québec, Canada.
Branch KRH; University of Washington Medical Center, Seattle, WA, USA.
Wang WJ; Comparative Health Outcomes, Policy and Economics Institute, School of Pharmacy, University of Washington, USA.
Bhatt DL; Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
Probstfield J; Division of Cardiology, University of Washinton, Seattle, WA, USA.
Ertl G; Department of Medicine I, University of Würzburg, WürzburgGermany.; Comprehensive Heart Failure Center, University Hospital, Würzburg, Germany.
Störk S; Department of Medicine I, University of Würzburg, WürzburgGermany.; Comprehensive Heart Failure Center, University Hospital, Würzburg, Germany.
Steg PG; Department of Cardiology, Université Paris Diderot, Paris, France.; Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France.
Aboyans V; Department of Cardiology, Dupuytren University Hospital, and Inserm 1094 & IRD, NET, Limoges University, Limoges, France.
Durand-Zaleski I; Assistance Publique Hôpitaux de Paris, URC Eco and Santé Publique, Hôpital Henri Mondor, Créteil, France.; Health Economics Research Unit, Université Paris Est Créteil, Créteil, France.; INSERM ECEVE UMR 1123, ParisFrance.
Ryden L; Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.
Yusuf S; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Pokaż więcej
Źródło:
European heart journal. Quality of care & clinical outcomes [Eur Heart J Qual Care Clin Outcomes] 2023 Aug 07; Vol. 9 (5), pp. 502-510.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Aspirin*/therapeutic use
Peripheral Arterial Disease*/drug therapy
Humans ; Cost-Benefit Analysis ; Drug Therapy, Combination ; Factor Xa Inhibitors/therapeutic use ; Rivaroxaban/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Biological Activities of Bismuth Compounds: An Overview of the New Findings and the Old Challenges Not Yet Overcome.
Autorzy:
Rosário JDS; Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil.
Moreira FH; Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil.
Rosa LHF; Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil.
Guerra W; Institute of Chemistry, Universidade Federal de Uberlândia, Campus Santa Mônica, Uberlândia 38400-142, MG, Brazil.
Silva-Caldeira PP; Department of Chemistry, Centro Federal de Educação Tecnológica de Minas Gerais, Belo Horizonte 30421-169, MG, Brazil.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Aug 07; Vol. 28 (15). Date of Electronic Publication: 2023 Aug 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Humans ; Bismuth/pharmacology ; Bismuth/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Vericiguat suppresses ventricular tachyarrhythmias inducibility in a rabbit myocardial infarction model.
Autorzy:
Chang PC; Department of Internal Medicine, Division of Cardiology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; Medical School, Chang Gung University, Taoyuan, Taiwan.
Lee HL; Medical School, Chang Gung University, Taoyuan, Taiwan.; Department of Anesthesia, Chang Gung Memorial Hospital, Taipei, Taiwan.
Wo HT; Department of Internal Medicine, Division of Cardiology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; Medical School, Chang Gung University, Taoyuan, Taiwan.
Liu HT; Department of Internal Medicine, Division of Cardiology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; Medical School, Chang Gung University, Taoyuan, Taiwan.
Wen MS; Department of Internal Medicine, Division of Cardiology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; Medical School, Chang Gung University, Taoyuan, Taiwan.
Chou CC; Department of Internal Medicine, Division of Cardiology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.; Medical School, Chang Gung University, Taoyuan, Taiwan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 16; Vol. 19 (4), pp. e0301970. Date of Electronic Publication: 2024 Apr 16 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Myocardial Infarction*/complications
Myocardial Infarction*/drug therapy
Tachycardia, Ventricular*/drug therapy
Heterocyclic Compounds, 2-Ring*
Pyrimidines*
Animals ; Rabbits ; Ventricular Fibrillation ; Calcium/therapeutic use ; Arrhythmias, Cardiac/drug therapy ; Anti-Arrhythmia Agents/therapeutic use ; Heart Block
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Autorzy:
Cheng Y; Xiangya Stomatological Hospital and Xiangya School of Stomatology, Central South University, Changsha, 410008, Hunan, China.; Clinical Research Center of Oral Major Diseases and Oral Health & Academician, Central South University, Changsha, 410008, Hunan, China.
Song Z; Xiangya Stomatological Hospital and Xiangya School of Stomatology, Central South University, Changsha, 410008, Hunan, China.; Clinical Research Center of Oral Major Diseases and Oral Health & Academician, Central South University, Changsha, 410008, Hunan, China.
Fang X; Xiangya Stomatological Hospital and Xiangya School of Stomatology, Central South University, Changsha, 410008, Hunan, China. .; Clinical Research Center of Oral Major Diseases and Oral Health & Academician, Central South University, Changsha, 410008, Hunan, China. .
Tang Z; Xiangya Stomatological Hospital and Xiangya School of Stomatology, Central South University, Changsha, 410008, Hunan, China. .; Clinical Research Center of Oral Major Diseases and Oral Health & Academician, Central South University, Changsha, 410008, Hunan, China. .
Pokaż więcej
Źródło:
Clinical epigenetics [Clin Epigenetics] 2024 Apr 10; Vol. 16 (1), pp. 54. Date of Electronic Publication: 2024 Apr 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Enhancer of Zeste Homolog 2 Protein*/antagonists & inhibitors
Enhancer of Zeste Homolog 2 Protein*/metabolism
Squamous Cell Carcinoma of Head and Neck*/drug therapy
Humans ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/metabolism ; DNA Methylation ; Epigenesis, Genetic ; Head and Neck Neoplasms/drug therapy ; Mouth Neoplasms/drug therapy ; Polycomb Repressive Complex 2/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of Limosilactobacillus fermentum probiotic treatment on gut microbiota composition in sahiwal calves with rotavirus diarrhea: A 16S metagenomic analysis study".
Autorzy:
Murtaza N; Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan.
Nawaz M; Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan. .
Yaqub T; Institute of Microbiology, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan.
Mehmood AK; Department of Veterinary Surgery and Pet Sciences, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan.
Pokaż więcej
Źródło:
BMC microbiology [BMC Microbiol] 2024 Apr 04; Vol. 24 (1), pp. 114. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
Rotavirus*/genetics
Rotavirus Infections*/drug therapy
Rotavirus Infections*/veterinary
Gastrointestinal Microbiome*/genetics
Limosilactobacillus fermentum*
Probiotics*/therapeutic use
Cattle Diseases*/drug therapy
Cattle Diseases*/microbiology
Animals ; Cattle ; Dysbiosis ; Diarrhea/drug therapy ; Diarrhea/veterinary ; Feces/microbiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Autorzy:
Fang HW; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Tseng PL; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Hu TH; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Wang JH; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Hung CH; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Lu SN; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan.
Chen CH; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Ta Pei Road, Kaohsiung, Taiwan. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2024 Apr 03; Vol. 21 (1), pp. 79. Date of Electronic Publication: 2024 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/prevention & control
Hematologic Neoplasms*/chemically induced
Hematologic Neoplasms*/drug therapy
Guanine/*analogs & derivatives
Humans ; Tenofovir/therapeutic use ; Antiviral Agents ; Hepatitis B e Antigens ; Viremia ; Rituximab/therapeutic use ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Recurrence, Local/chemically induced ; Neoplasm Recurrence, Local/drug therapy ; Hepatitis B virus ; Adenine/therapeutic use ; Treatment Outcome ; Recurrence ; Hepatitis B Surface Antigens
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dihydrotanshinone I exhibits antitumor effects via β-catenin downregulation in papillary thyroid cancer cell lines.
Autorzy:
Molteni E; Department of Medicine, University of Udine, 33100, Udine, Italy.
Baldan F; Department of Medicine, University of Udine, 33100, Udine, Italy. .
Damante G; Department of Medicine, University of Udine, 33100, Udine, Italy.; Institute of Medical Genetics, Academic Hospital of Udine, Azienda Sanitaria Universitaria Friuli Centrale, 33100, Udine, Italy.
Allegri L; Department of Medicine, University of Udine, 33100, Udine, Italy.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Apr 03; Vol. 14 (1), pp. 7853. Date of Electronic Publication: 2024 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Papillary*/drug therapy
Carcinoma, Papillary*/genetics
Carcinoma, Papillary*/metabolism
Thyroid Neoplasms*/drug therapy
Thyroid Neoplasms*/genetics
Thyroid Neoplasms*/metabolism
Furans*
Phenanthrenes*
Quinones*
Humans ; Thyroid Cancer, Papillary/drug therapy ; Thyroid Cancer, Papillary/pathology ; beta Catenin/genetics ; beta Catenin/metabolism ; Down-Regulation ; Cell Line, Tumor ; Wnt Signaling Pathway/genetics ; Cell Proliferation/physiology ; Cell Movement/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Low-dose aspirin for prevention of cardiovascular mortality in patients with type 2 diabetes and chronic kidney disease: A real-world nationwide cohort study.
Autorzy:
Lin YC; Department of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chen BL; Department of Pharmacy, Taipei Medical University Hospital, Taipei, Taiwan.; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chen WT; Health Data Analytics and Statistics Center, Office of Data Science, Taipei Medical University, New Taipei City, Taiwan.
Chien LN; Institute of Health and Welfare Policy, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Huang CY; Division of Cardiology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.; Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, Taiwan.; Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan.; Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; Department of Biomedical Science and Engineering, National Central University, Taoyuan City, Taiwan.
Pokaż więcej
Źródło:
Journal of diabetes investigation [J Diabetes Investig] 2024 Apr; Vol. 15 (4), pp. 459-467. Date of Electronic Publication: 2023 Dec 21.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/chemically induced
Cardiovascular Diseases*/epidemiology
Renal Insufficiency, Chronic*/complications
Renal Insufficiency, Chronic*/drug therapy
Atherosclerosis*/etiology
Kidney Failure, Chronic*/complications
Adult ; Humans ; Cohort Studies ; Retrospective Studies ; Reimbursement, Incentive ; Aspirin/therapeutic use ; Hemorrhage/chemically induced ; Hemorrhage/complications ; Hemorrhage/drug therapy ; Disease Progression
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Patients with chronic hepatitis B who have persistently normal alanine aminotransferase or aged < 30 years may exhibit significant histologic damage.
Autorzy:
Wei S; Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Foshan, 528308, China.; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China.
Xie Q; Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Foshan, 528308, China.
Liao G; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China.
Chen H; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China.
Hu M; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China.
Lin X; Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China.
Li H; Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Foshan, 528308, China.
Peng J; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510080, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2024 Mar 27; Vol. 24 (1), pp. 120. Date of Electronic Publication: 2024 Mar 27.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Humans ; Alanine Transaminase ; Hepatitis B e Antigens ; Retrospective Studies ; Fibrosis ; Liver Cirrhosis/drug therapy ; Antiviral Agents/therapeutic use ; Inflammation/drug therapy ; Hepatitis B virus/genetics ; DNA, Viral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Retinoic acid attenuates ischemic injury-induced activation of glial cells and inflammatory factors in a rat stroke model.
Autorzy:
Kang JB; Department of Anatomy and Histology, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Son HK; Department of Anatomy and Histology, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Shah MA; Department of Anatomy and Histology, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Koh PO; Department of Anatomy and Histology, College of Veterinary Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 25; Vol. 19 (3), pp. e0300072. Date of Electronic Publication: 2024 Mar 25 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Stroke*/drug therapy
Stroke*/metabolism
Brain Ischemia*/drug therapy
Neuroprotective Agents*/pharmacology
Neuroprotective Agents*/therapeutic use
Rats ; Male ; Animals ; Tumor Necrosis Factor-alpha/metabolism ; Tretinoin/pharmacology ; Tretinoin/therapeutic use ; Antioxidants/pharmacology ; Antioxidants/therapeutic use ; Neuroglia/metabolism ; Cytokines/metabolism ; Anti-Inflammatory Agents/therapeutic use ; Infarction, Middle Cerebral Artery/complications ; Infarction, Middle Cerebral Artery/drug therapy ; Infarction, Middle Cerebral Artery/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
Autorzy:
Liu T; Department of Coronary Heart Disease, Civil Aviation General Hospital, No. 1 Gaojingjia Road, Chaoyang District, Beijing, China.
Fan Z; Department of Coronary Heart Disease, Civil Aviation General Hospital, No. 1 Gaojingjia Road, Chaoyang District, Beijing, China. fanzy_.
Xiao B; Department of Coronary Heart Disease, Civil Aviation General Hospital, No. 1 Gaojingjia Road, Chaoyang District, Beijing, China.
He C; Department of Coronary Heart Disease, Civil Aviation General Hospital, No. 1 Gaojingjia Road, Chaoyang District, Beijing, China.
Wang S; Department of Coronary Heart Disease, Civil Aviation General Hospital, No. 1 Gaojingjia Road, Chaoyang District, Beijing, China.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Mar 25; Vol. 23 (1), pp. 106. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Acute Coronary Syndrome*/drug therapy
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Heart Failure*/diagnosis
Heart Failure*/drug therapy
Heart Failure*/epidemiology
Sodium-Glucose Transporter 2 Inhibitors*/adverse effects
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Cardiovascular Diseases/drug therapy ; Propensity Score
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Caffeic acid phenethyl ester inhibits neuro-inflammation and oxidative stress following spinal cord injury by mitigating mitochondrial dysfunction via the SIRT1/PGC1α/DRP1 signaling pathway.
Autorzy:
Zhang Y; Department of Orthopedics, Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
Deng Q; Department of Orthopedics, Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.; Postgraduate School, Nanjing University of Chinese Medicine, Nanjing, China.
Hong H; Department of Spine Surgery, Nantong First People's Hospital, The Second Affiliated Hospital of Nantong University, Research Institute for Spine and Spinal Cord Disease of Nantong University, No. 666, ShengLi Road, Chongchuan District, Nantong, Jiangsu, China.
Qian Z; Department of Orthopedics, Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China. .
Wan B; Department of Orthopedics, Northern Jiangsu People's Hospital Affiliated to Yangzhou University/Clinical Medical College, Yangzhou University, Yangzhou, China. .
Xia M; Department of Spine Surgery, Nantong First People's Hospital, The Second Affiliated Hospital of Nantong University, Research Institute for Spine and Spinal Cord Disease of Nantong University, No. 666, ShengLi Road, Chongchuan District, Nantong, Jiangsu, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Mar 25; Vol. 22 (1), pp. 304. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Caffeic Acids*/pharmacology
Caffeic Acids*/therapeutic use
Mitochondrial Diseases*/drug therapy
Mitochondrial Diseases*/metabolism
Phenylethyl Alcohol*/analogs & derivatives
Spinal Cord Injuries*/drug therapy
Animals ; Mice ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Anti-Inflammatory Agents/metabolism ; Inflammation/drug therapy ; Inflammation/metabolism ; Methylprednisolone/pharmacology ; Molecular Docking Simulation ; Oxidative Stress/drug effects ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/metabolism ; Reactive Oxygen Species/metabolism ; Signal Transduction ; Sirtuin 1/metabolism ; Spinal Cord ; Dynamins/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tanshinone IIA Alleviates Traumatic Brain Injury by Reducing Ischemia‒Reperfusion via the miR-124-5p/FoxO1 Axis.
Autorzy:
Su W; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Lv M; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Wang D; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
He Y; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Han H; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Zhang Y; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Zhang X; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Lv S; Rehabilitation Medicine of Qujing No. 1 Hospital, Qujing 655000, Yunnan, China.
Yao L; Department of Rehabilitation Medicine, The Second Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan, China.
Pokaż więcej
Źródło:
Mediators of inflammation [Mediators Inflamm] 2024 Mar 21; Vol. 2024, pp. 7459054. Date of Electronic Publication: 2024 Mar 21 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Brain Ischemia*/drug therapy
Brain Ischemia*/metabolism
MicroRNAs*/metabolism
Reperfusion Injury*/drug therapy
Reperfusion Injury*/complications
Brain Injuries, Traumatic*
Ischemic Stroke*
Abietanes*
Humans ; Rats ; Animals ; Infarction, Middle Cerebral Artery/drug therapy ; Infarction, Middle Cerebral Artery/metabolism ; Oxygen/metabolism ; Reperfusion/adverse effects ; Glucose/metabolism ; Water ; Apoptosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
Autorzy:
Ye D; Department of Pharmacy, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China.
Liang X; Phase 1 Clinical Trial Laboratory, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China.
Chen X; Department of Pharmacy, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China. .; Phase 1 Clinical Trial Laboratory, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China. .
Li Y; Department of Pharmacy, Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 21; Vol. 14 (1), pp. 6807. Date of Electronic Publication: 2024 Mar 21.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/drug therapy
Head and Neck Neoplasms*/drug therapy
Humans ; United States ; Nivolumab/therapeutic use ; Ipilimumab/therapeutic use ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Cost-Effectiveness Analysis ; Cost-Benefit Analysis ; Cetuximab
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 61-80 z 463972

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies